Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: A randomized, double-blind study

International Clinical Psychopharmacology

Volumn 28, Issue 5, 2013, Pages 267-274

  Lin, Ching Hua ^a,b,c   Wang, Fu Chiang ^a   Lin, Shih Chi ^a   Huang, Yu Hui ^a   Chen, Cheng Chung ^a   Lane, Hsien Yuan ^d,e  

^a Superintendent of Kaohsiung Kai Syuan Psychiatric Hospital   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c FOOYIN UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

amisulpride; antipsychotic combination; schizophrenia; sulpiride

Indexed keywords

AMISULPRIDE; BENZODIAZEPINE; BIPERIDEN; SULPIRIDE;

ADULT; AKATHISIA; AKINESIA; ARTICLE; ASTHENIA; BODY WEIGHT; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HUMAN; HYPOKINESIA; INSOMNIA; LIBIDO; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL DISEASE; MONOTHERAPY; NAUSEA AND VOMITING; POLYDIPSIA; POLYURIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; SALIVATION; SCHIZOPHRENIA; SIDE EFFECT; SLEEP TIME; SOMNOLENCE; TENSION; TREATMENT OUTCOME; TREMOR;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; COST SAVINGS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS, PSYCHIATRIC; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SULPIRIDE; TAIWAN;

EID: 84881557800     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283633a83     Document Type: Article

References (48)

1. Addington D, Addington J, Maticka-Tyndale E (1994). Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res 11:239-244
2. American Psychiatric Association (1994). Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press
3. Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano H, et al. (2010). Positron emission tomography measurement of dopamine D(2) receptor occupancy in the pituitary and cerebral cortex: Relation to antipsychoticinduced hyperprolactinemia. J Clin Psychiatry 71:1131-1137
4. Baandrup L, Lublin H, Nordentoft M, Glenthoj B (2011). Association of antipsychotic polypharmacy with health service cost: A register-based cost analysis. Eur J Health Econ 13:355-363
5. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
6. Blackwelder WC (1982). 'Proving the null hypothesis' in clinical trials. Control Clin Trials 3:345-353
7. Bratfos O, Haug JO (1979). Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study. Acta Psychiatr Scand 60:1-9
8. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T,Westlake L (1992). Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 305:160-164
9. Bressan RA, Erlandsson K, Spencer EP, Ell PJ, Pilowsky LS (2004). Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 175:367-373
10. Caley CF, Weber SS (1995). Sulpiride: An antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother 29:152-160
11. Copolov DL, Link CG, Kowalcyk B (2000). A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636,'Seroquel') and haloperidol in schizophrenia. Psychol Med 30:95-105
12. Edwards JG, Alexander JR, Alexander MS, Gordon A, Zutchi T (1980). Controlled trial of sulpiride in chronic schizophrenic patients. Br J Psychiatry 137:522-529
13. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J (2005). Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5:26-36
14. Forthofer RN, Lee ES, Hernandez M (2007). Biostatistics: A guide to design, analysis, and discovery. Burlington, MA: Elsevier Academic Press
15. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ (2010). International consensus study of antipsychotic dosing. Am J Psychiatry 167: 686-693
16. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, et al. (2009). Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 19:520-532
17. Guy W (1976). ECDEU assessment manual for psychopharmacology. DHEW Publication 76338. Washington, DC: DHEW
18. Haddad PM, Wieck A (2004). Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 64:2291-2314
19. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS (2003). Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects. Psychoneuroendocrinology 28 (Suppl 1):53-67
20. Jaffe AB, Levine J (2003). Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 12:41-48
21. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
22. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS (2002). The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats. J Pharmacol Exp Ther 302:1129-1134
23. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
24. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jorgensen HA (2009). Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 9:24
25. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE (2005). Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 62:1196-1204
26. Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lemperiere T, et al. (2001). Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 44:41-46
27. Leucht S, Pitschel-Walz G, Engel RR, KisslingW(2002). Amisulpride, an unusual 'atypical' antipsychotic: A meta-Analysis of randomized controlled trials. Am J Psychiatry 159:180-190
28. Lin CH, Kuo CC, Chou LS, Chen YH, Chen CC, Huang KH, Lane HY (2010). A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol 30:518-525
29. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-Treated patients. Acta Psychiatr Scand Suppl 334:1-100
30. Loosbrock DL, Zhao Z, Johnstone BM, Morris LS (2003). Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ 6:67-75
31. Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi G (1996). A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Saf 14:288-298
32. Meltzer HY, Busch DA, Fang VS (1983). Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 9:271-283
33. Meltzer HY, Fang VS (1976). The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33:279-286
34. Miller AL, Craig CS (2002). Combination antipsychotics: Pros, cons, and questions. Schizophr Bull 28:105-109
35. Mojtabai R, Olfson M (2010). National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67:26-36
36. 'Moos RH, Nichol AC, Moos BS (2002). Global Assessment of Functioning ratings and the allocation and outcomes of mental health services. Psychiatr Serv 53:730-737
37. Muller-Spahn F (2002). Current use of atypical antipsychotics. Eur Psychiatry 17 (Suppl 4):377-384
38. Pandurangi AK, Dalkilic A (2008). Polypharmacy with second-generation antipsychotics: A review of evidence. J Psychiatr Pract 14:345-367
39. Puech A, Fleurot O, Rein W (1998). Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 98:65-72
40. Rao VA, Bailey J, Bishop M, Coppen A (1981). A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology (Berl) 73:77-80
41. Rey MJ, Schulz P, Costa C, Dick P, Tissot R (1989). Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 4:95-104
42. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97
43. Schumacher JE, Makela EH, Griffin HR (2003). Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 37:951-955
44. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19
45. Stein G, Wilkinson G (2007). Seminars in general adult psychiatry. 2nd ed. Trowbridge,Wiltshire, UK: The Royal College of Psychiatrists. pp. 238-294
46. Tapp A,Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N (2003). Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54:55-59
47. Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008). Benefits and risks of antipsychotic polypharmacy: An evidence-based review of the literature. Drug Saf 31:7-20
48. Zink M, Englisch S, Meyer-Lindenberg A (2010). Polypharmacy in schizophrenia. Curr Opin Psychiatry 23:103-111